5,6,7,8-tetrahydro-naphthalene-1-sulfonyl chloride | 62686-69-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 5,6,7,8-tetrahydro-naphthalene-1-sulfonyl chloride
• 英文别名: 5,6,7,8-Tetrahydro-naphthalin-1-sulfonylchlorid；5,6,7,8-Tetrahydronaphthalene-1-sulfonyl chloride
• CAS: 62686-69-5
• 化学式: C₁₀H₁₁ClO₂S
• 分子量: 230.715
• InChiKey: WOJRSDINYVOLJK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5,6,7,8-tetrahydro-naphthalene-1-sulfonyl chloride 在 盐酸 、 氯化亚砜 、 potassium carbonate 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 氯仿 、 水 、 乙酸乙酯 、 苯 为溶剂， 反应 15.0h， 生成 N2-(5,6,7,8-tetrahydro-1-naphthalenesulfonyl)-L-arginyl-N-butylglycine
  参考文献：
  名称：

  凝血酶抑制剂。3.Nα-取代的L-精氨酸的含羧基的酰胺衍生物。

  摘要：

  制备了一系列具有羧基羧基酰胺N-取代基的Nα-（芳基磺酰基）-L-精氨酸酰胺衍生物，并测试了它们作为凝血酶凝血活性的抑制剂。当在Nα-（芳基磺酰基）-L-精氨酸酰胺衍生物（例如Nα-（芳基磺酰基）-L-精氨酸-N-丁基）的酰胺氮旁的碳原子中引入羧基时，获得最具抑制性的化合物。 -，N-（甲氧基乙基）-或N-（四氢糠基）甘氨酸和4-烷基-1- [Nα-（芳基磺酰基）-L-精氨酰基] -2-哌啶甲酸，I50为1-3 X 10（ -7）M.

  DOI：

  10.1021/jm00186a003
• 作为产物：
  描述：

  1,2,3,4-四氢萘 在 氯磺酸 作用下， 生成 5,6,7,8-tetrahydro-naphthalene-1-sulfonyl chloride
  参考文献：
  名称：

  Schroeter, Justus Liebigs Annalen der Chemie, 1922, vol. 426, p. 132

  摘要：

  DOI：

文献信息

• Thrombin inhibitors. 2. Amide derivatives of N.alpha.-substituted L-arginine
  作者：Ryoji Kikumoto、Yoshikuni Tamao、Kazuo Ohkubo、Tohru Tezuka、Shinji Tonomura、Shosuke Okamoto、Yoshinori Funahara、Akiko Hijikata

  DOI：10.1021/jm00182a004

  日期：1980.8

  with tetralin or an oxygen-containing heterocyclic compound as a N alpha-substituent showed an inhibition with an I50 less than 10(-5) M. N-Monosubstituted derivatives of N alpha-dansyl-L-arginine amide were not hydrolyzed at all by thrombin and were hydrolyzed very slowly by trypsin, and N,N-disubstituted derivatives were not hydrolyzed at all by both enzymes.

  制备了一系列具有取代或未取代的萘和杂环化合物作为Nα取代基的Nα-（芳基磺酰基）-L-精氨酸酰胺衍生物，并测试了它们作为凝血酶凝血活性的抑制剂。Nα-丹磺酰基-L-精氨酸酰胺的Nn-丁基和Nn-丁基-N-甲基衍生物对Nα-丹磺酰基-L-精氨酸酰胺的N-烷基和N，N-二烷基衍生物的抑制作用最大。它们的抑制作用与I50为2 X 10（-6）M的Nα-丹磺酰基-L-精氨酸-正丁酯的抑制作用一样。Nα-取代的4-甲基萘他磺酰基-L-精氨酸酰胺衍生物-和4-乙基哌啶也显示出有效的抑制作用，I50为10（-7）至10（-6）M。在该研究中，最有效的抑制作用是1- [Nα-（4,6-二甲氧基萘-2-磺酰基]-精氨酰基] -4-甲基哌啶，I50为7。
• Compounds, Process for their Preparation, Intermediates, Pharmaceutical Compositions and their use in the Treatment of 5-HT6 Mediated Disorders such as Alzheimer's Disease, Cognitive Disorders, Cognitive Impairment Associated with Schizophrenia, Obesity and Parkinson's Disease
  申请人：Nordvall Gunnar

  公开号：US20100105657A1

  公开（公告）日：2010-04-29

  The present invention relates to new compounds of formula (I), or salts, solvates or solvated salts thereof, process for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in the treatment of 5-HT6 mediated disorders such as Alzheimer's disease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and Parkinson's disease.

  本发明涉及公式（I）的新化合物，或其盐，溶剂合物或溶剂化盐，其制备过程以及用于制备其中间体的新方法，含有所述化合物的制药组合物以及所述化合物在治疗5-HT6介导的疾病，如阿尔茨海默病，认知障碍，与精神分裂症相关的认知障碍，肥胖症和帕金森病的用途。
• STAT3 INHIBITORS AND THEIR ANTICANCER USE
  申请人：Ohio State Innovation Foundation

  公开号：US20150232434A1

  公开（公告）日：2015-08-20

  In one aspect, the invention relates to substituted 6-amino-5,8-dioxo-5,8-dihydronaphthalene-1-sulfonamide analogs and derivatives thereof, substituted 4-amino-5H-naphtho[1,8-cd]isothiazol-5-one 1,1-dioxide analogs and derivatives thereof, and related compounds, which are useful as inhibitors of STAT protein activity; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders of uncontrolled cellular proliferation associated with a STAT protein activity dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本发明涉及替代的6-氨基-5,8-二氧代-5,8-二氢萘酚-1-磺酰胺类似物及其衍生物，替代的4-氨基-5H-萘并[1,8-cd]异噻唑-5-酮1,1-二氧化物类似物及其衍生物以及相关化合物，它们可用作STAT蛋白活性的抑制剂；制备这些化合物的合成方法；包含这些化合物的制药组合物；以及使用这些化合物和组合物治疗与STAT蛋白活性功能障碍相关的细胞不受控制增殖紊乱的方法。本摘要旨在作为特定领域搜索的工具，不限制本发明。
• SULFONAMIDE COMPOUND OR SALT THEREOF
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：EP3466934A1

  公开（公告）日：2019-04-10

  The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient. A compound represented by Formula (I) [wherein, X1 represents an oxygen atom or the like; X2 represents an oxygen atom; X3 represents -NH-; X4 represents a hydrogen atom or the like; R1 represents -C(R11)(R12)- or the like; R11 and R12 are the same or different and each represents a hydrogen atom or the like; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R4 represents a hydrogen atom or the like] or a salt thereof.

  本发明提供了一种具有核糖核苷酸还原酶抑制活性的新型磺酰胺化合物或其盐，以及含有该化合物作为活性成分的药物组合物。 由式(I)代表的化合物[其中，X1代表氧原子或类似物；X2代表氧原子；X3代表-NH-；X4代表氢原子或类似物；R1代表-C(R11)(R12)-或类似物；R11和R12相同或不同且各自代表氢原子或类似物；R2代表任选取代的C6-C14芳烃基团或类似物；R3代表任选取代的C6-C14芳烃基团或类似物；R4代表氢原子或类似物]或其盐。
• ANTITUMOR AGENT
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：EP3718545A1

  公开（公告）日：2020-10-07

  The present invention provides a method of enhancing an antitumor effect by a compound strongly inhibiting ribonucleotide reductase (RNR) or a salt thereof. A combination formulation involving combined administration of a sulfonamide compound represented by Formula (I) [In the formula, X1 represents an oxygen atom or the like; X2 represents an oxygen atom; X3 represents -NH-; X4 represents a hydrogen atom or the like; R1 represents -C(R11) (R12)- or the like; R11 and R12 are the same or different and each represents a hydrogen atom or the like; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R4 represents a hydrogen atom or the like] or a salt thereof, having RNR inhibitory activity, and other antitumor agent(s).

  本发明提供了一种通过强抑制核糖核苷酸还原酶（RNR）的化合物或其盐增强抗肿瘤效果的方法。 一种组合制剂涉及联合给药由式(I)代表的磺酰胺化合物[式中，X1代表氧原子或类似物；X2代表氧原子；X3代表-NH-；X4代表氢原子或类似物；R1代表-C(R11)(R12)-或类似物；R11和R12相同或不同，各自代表氢原子或类似物；R2代表任选取代的C6-C14芳烃基团或类似物；R3代表任选取代的C6-C14芳烃基团或类似物；R4代表氢原子或类似物]或其盐，具有RNR抑制活性，以及其他抗肿瘤剂。